Abstract：
BACKGROUND: Empagliflozin plays a beneficial role in individuals with type 2 diabetes at high risk of cardiovascular complications. This study aimed to assess the prevalence of individuals with type 2 diabetes who required empagliflozin based on clinical guidelines between the years 2022 and 2023.
METHODS: This study was a descriptive-analytical cross-sectional study conducted on a target population of patients with type 2 diabetes. Patient data, including demographic characteristics, smoking status, hypertension, hyperlipidemia, renal insufficiency, retinopathy, and proteinuria, were collected. The indication for prescribing empagliflozin was determined based on the risk of cardiovascular complications.
RESULTS: A total of 398 individuals with type 2 diabetes with a mean age of 58.4 years were examined. Overall, 87.4% of the patients had an indication for empagliflozin prescription. The indication for empagliflozin prescription was significantly higher in men, individuals with hyperlipidemia, those over 55 years of age, obese individuals, and smokers. The mean age, body mass index, and triglyceride levels were higher in candidates for empagliflozin prescription. Male candidates for empagliflozin had significantly higher rates of smoking and systolic blood pressure compared to females.
CONCLUSIONS: The findings of this study demonstrated that a significant percentage of individuals with type 2 diabetes had an indication for empagliflozin prescription based on clinical and laboratory criteria.
METHODS: This study was a descriptive-analytical cross-sectional study conducted on a target population of patients with type 2 diabetes. Patient data, including demographic characteristics, smoking status, hypertension, hyperlipidemia, renal insufficiency, retinopathy, and proteinuria, were collected. The indication for prescribing empagliflozin was determined based on the risk of cardiovascular complications.
RESULTS: A total of 398 individuals with type 2 diabetes with a mean age of 58.4 years were examined. Overall, 87.4% of the patients had an indication for empagliflozin prescription. The indication for empagliflozin prescription was significantly higher in men, individuals with hyperlipidemia, those over 55 years of age, obese individuals, and smokers. The mean age, body mass index, and triglyceride levels were higher in candidates for empagliflozin prescription. Male candidates for empagliflozin had significantly higher rates of smoking and systolic blood pressure compared to females.
CONCLUSIONS: The findings of this study demonstrated that a significant percentage of individuals with type 2 diabetes had an indication for empagliflozin prescription based on clinical and laboratory criteria.
摘要：
背景：Empagliflozin在心血管并发症高风险的2型糖尿病患者中起着有益的作用。这项研究旨在根据2022年至2023年的临床指南评估需要依帕列净的2型糖尿病患者的患病率。
方法：本研究是对2型糖尿病患者目标人群进行的描述性分析性横断面研究。患者数据,包括人口特征，吸烟状况,高血压,高脂血症,肾功能不全,视网膜病变,和蛋白尿，被收集。根据心血管并发症的风险确定处方依帕列净的适应症。
结果：共检查了398名平均年龄为58.4岁的2型糖尿病患者。总的来说,87.4%的患者有依帕列净处方的适应症。在男性中，依帕列净的适应症明显较高，患有高脂血症的个体，55岁以上的人，肥胖个体，和吸烟者。平均年龄,身体质量指数,依帕列净处方候选人的甘油三酯水平较高。与女性相比，empagliflozin的男性候选人的吸烟率和收缩压明显更高。
结论：这项研究的结果表明，根据临床和实验室标准，相当比例的2型糖尿病患者有依帕列净处方的适应症。
方法：本研究是对2型糖尿病患者目标人群进行的描述性分析性横断面研究。患者数据,包括人口特征，吸烟状况,高血压,高脂血症,肾功能不全,视网膜病变,和蛋白尿，被收集。根据心血管并发症的风险确定处方依帕列净的适应症。
结果：共检查了398名平均年龄为58.4岁的2型糖尿病患者。总的来说,87.4%的患者有依帕列净处方的适应症。在男性中，依帕列净的适应症明显较高，患有高脂血症的个体，55岁以上的人，肥胖个体，和吸烟者。平均年龄,身体质量指数,依帕列净处方候选人的甘油三酯水平较高。与女性相比，empagliflozin的男性候选人的吸烟率和收缩压明显更高。
结论：这项研究的结果表明，根据临床和实验室标准，相当比例的2型糖尿病患者有依帕列净处方的适应症。
